NASDAQ:DNLI
Denali Therapeutics Inc. Stock News
$20.24
-0.620 (-2.97%)
At Close: May 16, 2024
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
12:30pm, Monday, 13'th May 2024
Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks w
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
09:21am, Wednesday, 08'th May 2024
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
04:01pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cros
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
09:51am, Tuesday, 09'th Apr 2024
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
12:36pm, Thursday, 28'th Mar 2024
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
To the Moon and Beyond: 7 Stocks With Cosmic Potential
04:30pm, Thursday, 14'th Mar 2024
Stocks with moonshot potential are drawing attention amidst the current bullishness in the stock market. Despite the latest inflation reports pointing to a potential delay in the Federal Reserve's int
Denali: Leveraging Transport Vehicle Technology For Neurological Gains
10:05pm, Wednesday, 06'th Mar 2024
Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on tran
Top 3 Wall Street stock picks for March
08:51am, Wednesday, 06'th Mar 2024
While the stock market is not yet free of recessionary fears and remains affected by high interest rates, 2024 has, so far, brought significant positive developments if things are to be judged by majo
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
09:11am, Wednesday, 28'th Feb 2024
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
08:05am, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Denali Therapeutics Announces $500 million Private Placement Equity Financing
08:00am, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
09:10am, Thursday, 08'th Feb 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
